Meeting
2023 ASCO Genitourinary Cancers Symposium
Detection of true positive M1 lesions by 18F-rhPSMA-7.3 PET in newly diagnosed prostate cancer: Results from the phase 3 prospective LIGHTHOUSE study.
Authors
Bridget F. Koontz
Duke University Medical Center, Durham, NC
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Diagnostics and Imaging
Clinical Trial Registration Number
NCT04186819
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 315)
DOI
10.1200/JCO.2023.41.6_suppl.315
Abstract #
315
Poster Bd #
K15
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery.
First Author: Tobias Maurer
Poster
2021 ASCO Annual Meeting
Diagnostic performance of Gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging in early-relapsed prostate cancer: Phase 3, prospective, multicenter study (IAEA-PSMA study).
First Author: Juliano J Cerci
Poster
2024 ASCO Genitourinary Cancers Symposium
Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.
First Author: Michael Leapman
Poster
2024 ASCO Genitourinary Cancers Symposium
Update from the PSMA-dRT trial: A randomized phase III trial of PSMA-PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer.
First Author: John Nikitas